

# Inhibition of JAK3/STAT3 Activation in Rats Uterine Leiomyoma by formula of Taohong Siwu Decoction: A Randomized Controlled Trial

**Li Luo**

Chengdu University of Traditional Chinese Medicine Wenjiang Campus: Chengdu University of Traditional Chinese Medicine

**Shasha Shi**

Chengdu University of Traditional Chinese Medicine Wenjiang Campus: Chengdu University of Traditional Chinese Medicine

**Li Zhang**

Chengdu University of Traditional Chinese Medicine Wenjiang Campus: Chengdu University of Traditional Chinese Medicine

**Xun Xu**

Chengdu University of Traditional Chinese Medicine Wenjiang Campus: Chengdu University of Traditional Chinese Medicine

**Fu Peng**

Sichuan University

**Chenghao Yu** (✉ [yuholy@126.com](mailto:yuholy@126.com))

Chengdu University of Traditional Chinese Medicine <https://orcid.org/0000-0002-5793-1864>

**Liangwen Li**

Chengdu University of Traditional Chinese Medicine Wenjiang Campus: Chengdu University of Traditional Chinese Medicine

**Tie Zheng**

Tsinghua University

---

## Research

**Keywords:** Uterine leiomyoma, Taohong Siwu Decoction, JAK3, STAT3, Immune checkpoi

**Posted Date:** August 10th, 2021

**DOI:** <https://doi.org/10.21203/rs.3.rs-786708/v1>

**License:** © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

---



1 **Inhibition of JAK3/STAT3 activation in rats Uterine**  
2 **Leiomyoma by formula of Taohong Siwu Decoction: A**  
3 **randomized controlled trial**

4 **Li Luo<sup>1</sup>, ShaSha Shi<sup>1</sup>, Li Zhang<sup>1</sup>, Xun Xu<sup>2</sup>, Fu Peng<sup>3\*</sup>, ChengHao Yu<sup>1,4\*</sup>, LiangWen Li<sup>1</sup>, Tie**  
5 **Zheng<sup>5</sup>**

6 <sup>1</sup>Basic Medicine College, Chengdu University of Traditional Chinese Medicine, Chengdu, China

7 <sup>2</sup>Basic Medicine College, Yunnan University of Traditional Chinese Medicine, Yunnan, China

8 <sup>3</sup>West China School of Pharmacy, Sichuan University, Sichuan, China

9 <sup>4</sup>State Key Laboratory of Southwestern Chinese Medicine Resources, Sichuan, China

10 <sup>5</sup>School of Environment, State Key Joint Laboratory of Environment Simulation and Pollution Control,  
11 Tsinghua University, Beijing, China

12 **\* Correspondence:**

13 Fu Peng

14 [fujing126@yeah.net](mailto:fujing126@yeah.net).

15 Chenghao Yu

16 [yuholy@126.com](mailto:yuholy@126.com).

17

18 **Abstract**

19 **Background:** Traditional Chinese medicine (TCM) formula of Taohong Siwu decoction (THSW) is  
20 often used in traditional Chinese medicine for the treatment of uterine leiomyoma (UL). The  
21 effectiveness of THSW for the treatment of UL has been confirmed in previous studies. At present,  
22 there are few relevant mechanism studies. The purpose of this study is to explore the efficacy and  
23 mechanism of THSW in the treatment of uterine leiomyoma.

24 **Methods:** A Sprague Dawley (SD) rat model of UL was established via estrogen and progesterone load  
25 combined with external stimulation for 5 weeks. We randomly assigned adult female non-pregnant rats  
26 into six groups: a control group, a UL model group, and a positive drug group, THSW(18g/ml) group,  
27 THSW(9g/ml) group, THSW(4.5g/ml) group. THSW group and positive drug group were treated with  
28 THSW medicinal solutions and gongliuxiao capsule medicinal solutions respectively after daily  
29 modeling for 3 weeks. Histological analyses, Polymerase Chain Reaction and western blotting were  
30 performed to evaluate the effect of THSW on UL and elucidate its mechanism of action.

31 **Results:** The uterus morphology of the model group showed significantly more swelling than that of  
32 the control group, and pathological of changes of rats were obvious in the model group. Compared with

33 model group, the pathological changes of UL were relieved in the THSW group. Our data showed that  
34 the treatment of rats with THSW significantly reduced the expression of cytotoxic T lymphocyte  
35 associated antigen 4 (CTLA4) and indoleamine 2, 3-dioxygenase 1 (INDO). The phosphorylation of  
36 JAK3 and STAT3 which are the main signal transduction molecule of cytokines and growth  
37 factors were also inhibited.

38 **Conclusions:** Our results suggest that THSW is effective in the prevention and treatment of UL in rats,  
39 and THSW may exert its functions by inhibiting the activation of Tumor-related signal transduction  
40 pathway (JAK3/STAT3), immune escape, proliferation of tumor cell and improving apoptosis.

41 **Keywords: Uterine leiomyoma, Taohong Siwu Decoction, JAK3, STAT3, Immune checkpoint**

## 42 INTRODUCTION

43 Uterine leiomyoma, also known as uterine fibroma, is the most common benign tumors in women of  
44 child-bearing age, mainly caused by the proliferation of smooth muscle cells [1]. The incidence of the  
45 UL is on the rise, and the population of the UL is gradually younger [2]. The incidence rate of women  
46 was 20.0%-25.0% and 25.0%~50.0% of patients showed clinical symptoms [3], such as, abnormal  
47 uterine bleeding, lower abdominal pain, and even infertility or abortion. A very small number of UL  
48 malignant could become sarcoma, accounting for about 0.5% of uterine fibroids [4]. Studies have  
49 shown that women with UL are usually more likely than normal women to feel depressed and restless,  
50 and have a higher risk of depression [5], which seriously affects women's physical and mental health.  
51 The global economic expenditure caused by UL is about \$5.9-34.4 billion annually [6]. UL have  
52 become a problem related to health and socio-economic all over the world. Due to the lack of  
53 understanding of the underlying pathobiology, there is currently no fine medical treatment [7-9]. The  
54 current medical treatment of UL is mainly divided into surgical resection and drug treatment. Currently,  
55 the mainstream theory believes that UL is a hormone-dependent tumor. Therefore, the medical  
56 treatment of UL mainly is inhibiting steroid hormones at present, which has certain effect, but once the  
57 use is stopped, there is a high tendency of recurrence. About three quarters of UL are treated with  
58 hysterectomy [10]. Studies have shown [11] that there is ~28% risk of surgical complications. In some  
59 studies [12], the recurrence rate of surgery was more than 62%. In the United States, the lifetime risk of  
60 myomectomy is 45% higher [13]. Therefore, the conventional Western medicine has the characteristics  
61 of high recurrence rate, a lot of side effects and many complications at present. In fact, only 10% to  
62 20% of UL patients need surgery. Therefore, it is important to find an effective and safe treatment for  
63 UL. Replacement therapy such as TCM may eliminate the need of surgery treatment [14]. In this study,  
64 we used a rat model of qi stagnation and blood stasis UL, in which UL was induced via estrogen and  
65 progesterone load combined with external stimulation [15]. This model is more consistent with the  
66 pathological of human uterine leiomyoma.

67 Signal transduction, apoptosis and proliferation are one of the focuses of modern oncology. In  
68 addition, the mechanism of excessive proliferation in uterine smooth muscle cells and deposition of  
69 extracellular matrix is tightly regulated by a complex network, including cytokines, growth factors,  
70 MMP and TGF-  $\beta$  *etc.*. Current studies have shown that JAK3 belongs to a member of non-receptor  
71 tyrosine protein kinase family. and is mediated by cytokine and growth factor-initiated signals via the  
72 JAK/STAT pathway. JAK3 is mainly expressed in hematopoietic cells and immune cells, as well as in  
73 vascular cells and cancer cells, and is involved in cell proliferation, apoptosis and immune regulation

74 [16] It is a key mediator in regulating cells of metabolism and development and immune response  
75 [17,18]. In addition, JAK3 can affect the occurrence and development of diseases through various ways.  
76 The overexpression of JAK3 can induce vascular smooth muscle proliferation [19]. Sustained  
77 activation of JAK/STAT signal leads to increased expression of MMP [20]. These pathways are closely  
78 related to the formation of UL.

79 STAT3 is an important part of signal transduction and transcriptional activation, which plays an  
80 important role in the process of apoptosis and angiogenesis. It can mediate the interactive dialogue  
81 between tumor cells and immune cells, and is related to tumor invasion, metastasis, and immune escape.  
82 STAT3 plays a key role in tumor, including inhibition of apoptosis, alteration of cell cycle, and  
83 mediating angiogenesis and immunosuppression. Studies have shown that STAT3 can inhibit  
84 anti-tumor immunity by up-regulating apoptosis suppressor genes. STAT3 can also inhibit the  
85 pro-inflammatory cytokines produced by tumor cells, contribute to immune escape and promote the  
86 occurrence of tumor [21]. Continuous activation of STAT3 can promote tumor neovascularization [4,22]  
87 In addition, JAK / STAT pathway can regulate growth factors such as VEGF, TGF, IGF and matrix  
88 metalloproteinases to promote cell proliferation and survival and inhibit apoptosis, which is closely  
89 related to the occurrence and development of UL [23]. There is now increasing evidence to support the  
90 important role of the STAT in tumors [24-26]. Therefore, there is a theoretical basis for exploring the  
91 signal transduction and transcriptional activation of JAK/STAT. However, there are few studies on the  
92 expression of JAK/STAT in UL at home and abroad. Because excessive proliferation of smooth muscle  
93 cells leads to the development of UL, we hypothesized that UL can be inhibited by inhibiting JAK3 /  
94 STAT3 activation. This study preliminarily explored the expression of JAK/STAT in UL, providing  
95 evidence for further study on the pathogenesis of UL. The results of this study will provide  
96 experimental basis for the treatment of UL with TCM.

97 Uterine fibroids in TCM theory is considered to be caused by stagnation of Qi and blood.  
98 Promoting blood circulation and metabolism is the fundamental method of treating UL in TCM [22,27].  
99 Studies have shown that peach kernel, red peony root, poria cocos, zedoary turmeric, peony bark,  
100 sparganium, angelica, cyperus, cinnamon twig and oyster are the most frequently used for the treatment  
101 of UL, most of which are used for promoting blood circulation and removing blood stasis. Modern  
102 pharmacological studies have confirmed that the herbs which can promote blood circulation can  
103 improve hemorheological properties [28], thus reducing the size of UL. THSW is composed of peach  
104 kernels, safflower, peony, chuanxiong, dried ground and angelica. It has the effect of promoting blood  
105 circulation and tonifying qi and blood. It has a history of thousands of years and has good clinical  
106 efficacy in the treatment of gynecological diseases such as uterine fibroids and endometriosis. Modern  
107 pharmacological studies have confirmed that THSW has effects such as improving blood status,  
108 regulating immune function, regulating uterine smooth muscle, anti-oxidation, anti-inflammation,  
109 anti-cancer, anti-fibrosis and so on [29]. Shaoyun Li [30] found that THSW in the treatment of UL can  
110 significantly improve the therapeutic effects and reduce the size of fibroids. In addition, THSW can  
111 effectively improve the symptoms related to UL and improve the quality of life of patients with almost  
112 no side effects. Although THSW show a good effect in the treatment of UL in clinical, its mechanism of  
113 action is still unclear due to the characteristics of multi-channel and multi-target of TCM. Therefore, it  
114 is of great significance to understand the above signal pathway and related protein expression as one of  
115 the pathways of THSW in the treatment of UL.

116

## 117 **MATERIALS AND METHODS**

### 118 **Preparation of Herbal Decoction**

119 The medicinal materials (peach kernel, safflower, chuanxiong, red peony root, cooked ground, and  
120 angelica = 1:1:1:1:1) (Kangmei Pharmaceutical Co., Ltd, 200101811) were crushed, soaked in water  
121 for 2 h, and the residue was decocted twice: 1 h for the first extraction, 0.5h for the second extraction.  
122 After the mixture was mixed and filtered, the solution was concentrated to 18g/ml,9g/ml,4.5g/ml  
123 separately and stored at 4°C.The medicine in gongliuxiao capsule (Shandong step size Shenzhou  
124 Pharmaceutical Co., Ltd, z20055635) was poured into the mortar, ground thoroughly, dissolved with  
125 appropriate amount of ultrapure water, and mixed evenly to obtain 0.09g/ml medicine liquid, which  
126 was put in the refrigerator at 4 °C for standby.

127

### 128 **Rats**

129 Rats were cared for and tested in accordance with the plan approved by the Animal Ethics Committee  
130 of Chengdu University of Traditional Chinese Medicine. Female SD rats without specific pathogen  
131 [animal license number SYXK (Chuan) 2019-049] were purchased from Animal Experimental Center  
132 of Chengdu University of Traditional Chinese Medicine (China). All experiments were approved by the  
133 Animal Health and Use Committee of Chengdu University of Traditional Chinese Medicine. All  
134 animals were anesthetized with 2% sodium pentobarbital (0.25 mL /100 g) and killed through cervical  
135 dislocation after 5 weeks. We monitored the diet, weight, and general behavior of the rats weekly.

136

### 137 **Study Design**

138 Forty-two SD rats(220-250g) were randomly divided into 6 groups: control group(n=7), model  
139 group(n=7), positive drug group(n=7), THSW(18g/ml) group(n=7), THSW(9g/ml) group(n=7),  
140 THSW(4.5g/ml) group(n=7). Rats were kept in the Center of Laboratory Animals at Chengdu  
141 University of TCM. Gongliuxiao capsule was used as the positive drug. The UL model was established  
142 on the basis of adaptive feeding. The UL model was established using methods previously  
143 validated(11). Rats in the control group received no treatment. The other 5 groups were given  
144 intramuscular injection of estradiol benzoate (Ningbo No.2 hormone factory, 2003251) with 0.5mg/kg  
145 daily and intramuscular injection of progesterone (Ningbo No.2 hormone factory, 2003242) with  
146 1mg/kg every two days for 5 weeks. From the fourth week, the rats in the five experimental groups  
147 were subcutaneously injected with adrenaline hydrochloride (Ningbo No.2 hormone factory, 200311)  
148 with 0.5mg/kg/d, and 4 h after injection, external stimulation was applied once: (1) day and night  
149 reversal, (2) continuous stimulation with 60 dB noise for 3h, (3) continuous upside down for 10  
150 minutes, and (4) water bath at 5-10°C for 4 minutes. This went on for two weeks; Each stimulus was  
151 applied  $\geq 2$  times over 2 weeks. At the beginning of modeling, the drugs (10ml/kg) were administered  
152 simultaneously to the intervention group by gavage and to the appropriate group separately. The control  
153 group was given distilled water (Sichuan Kelun Pharmaceutical Co., Ltd, L218070808)2ml daily. The  
154 rats in the model group were not given drug intervention. After 5 weeks, the rats were anesthetized and  
155 the uterus was removed.(Figure1)

156

### 157 **Specimen Harvest**

158 At the end of the experiment, the rats were sacrificed after an overnight fast, the rats were anesthetized  
159 by 2% sodium pentobarbital (0.25 mL /100 g). We stripped the uterus, removed the surface adipose  
160 tissue, removed the blood with normal saline, and then measured. We measure the transverse diameter  
161 and diameter with vernier calipers. After measurement, we divided the uterus into three parts and put  
162 them into the corresponding fixative.

163

#### 164 **Histological Analyses**

165 It was embedded in paraffin, sectioned, blocked with a blocking buffer and stained. Then it was stained  
166 with hematoxylin (Wuhan Google Biotechnology Co., Ltd, G1005) for 3-7 minutes, and then stained  
167 with eosin (Wuhan Google Biotechnology Co., Ltd, G1005) for 4 minutes. The uterus was fixed  
168 overnight in 4% paraformaldehyde. The sections images were analyzed with a digital photographic  
169 microscope (BA400Digital; Mike Audi Industry Group Co., Ltd.).

170

#### 171 **Western Blotting**

172 The uterine tissue was ground into homogenate and centrifuged. The supernatant was taken for testing,  
173 and the protein was detected using the BCA protein quantitative kit (Hangzhou Lianke Biotechnology  
174 Co. Ltd, 70-PQ0012). The PVDF membrane (0.45um)(millipore, IPVH00010) was used to transfer the  
175 membrane. After incubation by 1:3000 primary antibody of CTLA4 (anti-rabbit, bioss, bs-10006R),  
176 INDO (anti-rabbit, Affinity, DF6502) for 4h, the protein was incubated again by 1:3000 secondary  
177 antibody (Hangzhou Lianke Biotechnology Co., Ltd, 70-GAR007) labeled with HRP for 30min. Finally,  
178 chemicope analysis was used for gray analysis.  $\beta$ -actin was selected as the loading control for protein  
179 expression analyses.

180

#### 181 **Polymerase Chain Reaction**

182 Total RNA in the uterine tissue was extracted via TRIzol (invitrogen, 15596018).  
183 Reverse-transcription of mRNA was performed using the PrimeScript RT Reagent Kit with gDNA  
184 Eraser. Real-time PCR experiments were performed using the SYBR Green master mix (ABM,  
185 019484830001). GAPDH was selected as the loading control for mRNA expression analyses. The  
186 corresponding primers for detecting JAK3, STAT3 and GAPDH are listed in Table S1.

187

#### 188 **Statistical Analysis**

189 All data were statistically analyzed by SPSS 23.0. We used one-way analysis of variance (ANOVA) if  
190 the variances are homogeneous. Otherwise, nonparametric validation is used. The results are expressed  
191 as mean  $\pm$  standard deviation. We considered  $p < 0.05$  as statistically significant.

192

## 193 **RESULTS**

### 194 **Establishment of the Rat Model**

195 In control group, all rats were in good physical and mental health. The rats in the model group showed  
196 large area of hair loss and weight loss, reduced food intake, or hyperactivity. The transverse and  
197 longitudinal diameters of the uterus in the model group increased, and the size of UL also increased  
198 significantly(Figure2 and Figure3). Pathological examination showed that compared with the control  
199 group, part of the endometrium epithelial cells in the model group were necrotic and abscisic, with

200 local smooth muscle cells hyperplasia and disordered arrangement, accompanied by a small amount of  
201 neutrophil infiltration. The uterus of rats in the model group (Figure 4B) was dull and transparent, with  
202 asymmetry and uneven thickness on both sides of the uterus. Also the uterus of rats in the model group  
203 was serious distortion and deformation, and obvious edema and nodules. Compared with the model  
204 group, the pathological state described above in the intervention group was improved to varying  
205 degrees.

206

#### 207 **Effects of THSW on the Appearance of the Uterus in Rats**

208 Compared with the model group (Figure 4B), the uterine edema of rats in intervention group (Figure  
209 4C-4E) was alleviated. Most of uterus were symmetrical and uniform thickness. Compared with the  
210 model group, the texture became soft and the surface of uterus was more smooth, and the volume of  
211 uterus became smaller, except for the THSW(4.5g/ml) group (Figure 4F). It may be that low-dose drugs  
212 have less therapeutic effect.

213

#### 214 **Effects of THSW on Histological Changes of the Uterus**

215 In the model group (Figure 5B) the endometrial epithelial cells were more necrotic and exfoliated.  
216 Local uterine smooth muscle cells were hyperplastic and disordered with a small amount of neutrophil  
217 infiltration. In the positive drug group (Figure 5C), a few endometrial epithelial cells were necrotic and  
218 neutrophils in lamina propria were increased. The smooth muscle cells of the myometrium was  
219 regularly arranged. Increased neutrophils were seen in the lamina propria in THSW (18g/ml) group  
220 (Figure 5D). The smooth muscle cells of the myometrium were arranged slightly irregularly with only a  
221 small amount of neutrophils infiltration in the lamina propria. A large number of neutrophils were seen  
222 in the lamina propria in THSW (9g/ml) group (Figure 5E). Local smooth muscle cells were  
223 hyperplastic and regularly arranged. Increased neutrophils were seen in the endometrium lamina  
224 propria in THSW (4.5g/ml) group (Figure 5F). Local smooth muscle cells were hyperplastic and  
225 disordered. These results suggest that THSW (18g/ml) and THSW (9g/ml) can significantly improve  
226 the histological status of UL.

227

#### 228 **Effect of THSW on activation of JAK3 and STAT3 of the Uterus**

229 Fluorescence quantitative PCR analysis showed that the expression of JAK3 in model group was  
230 significantly increased compared with control group ( $P < 0.01$ ). Compared with the model group, the  
231 expression of JAK3 was also decreased in THSW(4.5g/ml) group, but the difference was not  
232 statistically significant ( $P > 0.05$ ). The effect of THSW on the expression of JAK3 was dose-dependent,  
233 so the THSW(4.5g/ml) had a weak inhibitory effect on the overactivation of JAK3. Compared with the  
234 model group, the expression of JAK3 was significantly decreased after treatment with THSW (18g/ml)  
235 and THSW (9g/ml) ( $P < 0.001$ ). The positive control group had similar inhibitory effect on JAK3  
236 overactivation ( $P < 0.01$ ). (Figure 6)

237 Compared with the control group, the expression of STAT3 in the model group ( $P < 0.001$ ) was  
238 significantly increased, and the difference was statistically significant. Compared with the model group,  
239 the expression of STAT3 in the positive drug group ( $P < 0.05$ ) and THSW (9g/ml) ( $P < 0.05$ ) was  
240 significantly decreased, and the difference was statistically significant. The expression of STAT3 in  
241 THSW(18g/ml) group ( $P > 0.05$ ) and THSW (4.5g/ml) group ( $P > 0.05$ ) had a decreasing trend, but the



242 difference was not statistically significant (Figure 7).

243

#### 244 **Effect of THSW on the Expression of INDO/CTLA4 in the Uterus**

245 Western blot analysis showed that compared with model group, the expression of INDO was  
246 significantly decreased after treatment of THSW ( $P < 0.05$ ). The expression of INDO in model group  
247 was significantly higher than that in control group ( $P < 0.01$ ). In the positive group, the expression of  
248 INDO was similar to that in the drug intervention groups ( $P < 0.01$ ) (Figure 8B). Western blot analysis  
249 showed that compared with the model group, the expression of CTLA4 in uterine of the drug  
250 intervention group and the positive drug group was significantly decreased, but the difference was not  
251 statistically significant ( $P > 0.05$ ). The effect of CTLA4 in the positive group and the drug intervention  
252 group was similar. Compared with the control group, CTLA4 was significantly increased in the model  
253 group, however, the difference was not statistically significant ( $P > 0.05$ ). It may be because the drug  
254 intervention time is not enough. (Figure 8C)

255

#### 256 **DISCUSSION**

257 At present, researches on the etiology and pathogenesis of uterine fibroids at home and abroad mainly  
258 include: sex hormones and receptors, cell proliferation and apoptosis, abnormal expression of proto  
259 oncogenes, signal transduction, molecular genetics and related gene expression, MMP *etc.* [31]. At  
260 present, the mainstream theory believes that UL are estrogen-dependent tumors. Studies have  
261 shown that the role of hormones in cell proliferation and differentiation is regulated by a variety of  
262 growth factors. Due to the involvement of JAK / STAT in the signal transduction pathways of a variety  
263 of growth factors and hormones, the abnormal activation of this pathway is closely related to the  
264 occurrence, development and prognosis of a variety of diseases. However, as far as we know, no report  
265 has evaluated the effect of THSW on the expression of JAK3 and STAT3 in UL. Therefore, in this study,  
266 we aimed to address this issue using a well-established rat model of UL. Morphological and  
267 pathological data showed that THSW treatment significantly improved the symptoms of UL. Therefore,  
268 we further investigated whether THSW can improve UL by inhibiting the activation of JAK3 and  
269 STAT3. Activation of JAK3 leads to the occurrence and development of many tumors. Studies have  
270 shown that [32] inhibiting the phosphorylation of JAK3 can reduce the activity of tumor cells. Wang  
271 Yiqi and Liu Minghua *et al.* [33,34] found in their studies that TCM can reduce the proliferation and  
272 migration of tumors by inhibiting the JAK/STAT3 pathway, promote cell apoptosis, and inhibit the  
273 migration and invasion of tumor cells. Shushan *et al.* [35] also found that the addition of a tyrosine  
274 kinase inhibitor to uterine fibroid cells *in vitro* culture significantly inhibited the activation of STAT3,  
275 which in turn inhibited the proliferation of uterine fibroid cells, suggesting that STAT3 is a potential  
276 biomarker of UL. In addition, some studies have found that [36] activated STAT3 can improve the  
277 transcriptional activity of estrogen receptor and progesterone receptor, which may be involved in the  
278 pathological process of uterine fibroids. In Li Cairong's study [37], STAT3 was found to be involved in  
279 the regulation of proliferation and differentiation of uterine fibroids, tumor angiogenesis and cell cycle  
280 *etc.*. In fact, the results of real-time PCR showed that in each group of THSW, the expression of JAK3  
281 and STAT3 in utero was significantly reduced, indicating that JAK3 and STAT3 could be inhibited by  
282 THSW, which inhibited tumor proliferation and promoted apoptosis.

283 Immune escape is an important cause of tumor formation. Immune checkpoint related to immune

284 escape are a class of inhibitory receptors located on the surface of immune cells. Their function is to  
285 prevent autoimmunity caused by excessive activation of immune function, which is utilized by tumor  
286 cells, and tumor cells produce corresponding ligands to bind to it [38]. Subsequently, the activity of  
287 immune cells can be reduced. Studies have found that overexpression of JAK / STAT pathway can  
288 promote the expression of immune checkpoint. CTLA4 and INDO are immune checkpoints that have  
289 been studied deeply in recent years. INDO can directly inhibit the immune activity of T cells, or  
290 indirectly inhibit the activity of T cells by accelerating tryptophan depletion [39]. CTLA4 can block the  
291 pathway of T cell activation and has a negative regulatory effect on T cell activation [40]. Immune  
292 checkpoints are closely related to the occurrence and development of tumors. In the experiment of Sho  
293 *et al.* [41], it was demonstrated that CTLA4 plays an important role in inducing immune tolerance.  
294 Rigas *et al.* [19] injected complete anti-human CTLA4 MABCP-675 , 206 intravenously into tumor  
295 patients and observed that the anti-tumor immune effect in patients was increased and the disease was  
296 controlled. Some studies have also found [32] that TCM can treat uterine fibroids by inhibiting the  
297 expression of INDO. Our data showed that the expression levels of INDO and CTLA4 increased in the  
298 model group, and decreased after the treatment of THSW, indicating that THSW inhibited the  
299 expression of INDO and CTLA4, thus inhibiting the development of UL. This result is consistent with  
300 our findings. These results suggest that the therapeutic effect of THSW on UL may be related to the  
301 inhibition of JAK3 and STAT3 which can inhibit the expression of CTLA4 and INDO.

302 It is critical that the clinical treatment of uterine fibroids will change significantly in the future.  
303 The field needs to move towards the development of individualised treatment, as well as early  
304 intervention. In the recent decades, herbs and extractions from TCM, are gaining acceptance as  
305 promising complementary and alternative medicines for numerous diseases treatment [42-45]. The  
306 application of TCM can well achieve early intervention of symptoms and individualized treatment for  
307 different individuals. The application of TCM will have a positive impact on the intervention and  
308 treatment of uterine fibroids, which has also been confirmed in the experiment. In the next step, we  
309 should expand the clinical application of Taohong Siwu Decoction and conduct relevant cell  
310 experiments to obtain more accurate clinical guidance data.

311

## 312 **CONCLUSION**

313 The results showed that THSW could significantly improve the macroscopic pathological state of  
314 uterus in UL rats. The expression levels of JAK3 and STAT3, the major signal transduction molecules  
315 of cytokines and growth factors, were decreased in utero. It also reduced the expression of INDO and  
316 CTLA4. It was found that THSW could treat UL by inhibiting the activation of JAK3 and STAT3 and  
317 the expression of INDO/CTLA4. These data may provide a new way of thinking and treatment for  
318 laying a foundation for further study on the treatment of UL.

319

## 320 **Abbreviations**

321 **TCM:** Traditional Chinese medicine

322 **THSW:** Taohong Siwu decoction

323 **UL:** uterine leiomyoma

324 **JAK3:** Janus Kinase 3

325 **STAT3:** Signal transducer and activator of transcription 3

326 **SD:** Sprague Dawley  
327 **CTLA4:** cytotoxic T lymphocyte associated antigen 4  
328 **INDO:** indoleamine 2, 3-dioxygenase 1  
329

### 330 **Ethics Statement**

331 The animal study was reviewed and approved by the Animal Ethical Committee at the Chengdu  
332 University of Traditional Chinese Medicine.

333

### 334 **Consent for publication**

335 Not applicable.

336

### 337 **Data Availability Statement**

338 The datasets used and analysed during the current study are available from the corresponding author on  
339 reasonable request.

340

### 341 **Competing interests**

342 The authors declare that they have no competing interests.

343

### 344 **Funding**

345 This work was supported by the National Natural Science Foundation of China (Nos. 81001668 &  
346 81673878), Sichuan Youth Science and Technology Innovation Research Team Project  
347 (2020JDTD0022), Sichuan Provincial Department of Education Project(18ZA0189), and  
348 Youth Talent Promotion Project of China Association for Science and Technology  
349 (CACM-2020-QNRC1-01).

350

### 351 **Author Contributions**

352 LL and SS conceived and designed the experiment. LL and SS carried out the experiment. LL retrieved  
353 the relevant literature and wrote the manuscript. LL and XX analyzed the experimental data and drew  
354 pictures. FP, LL, CY, LZ and TZ provided helpful comments and revised the manuscript. All authors  
355 contributed to the article and approved the submitted version.

356

### 357 **Acknowledgements**

358 I would like to extend my sincere thanks to all those who have helped me make this thesis possible and  
359 better. I also would like to extend my sincere thanks to all fundings.

360

### 361 **References**

- 362 [1] Holdsworth-Carson, S. J., Zaitseva, M., Vollenhoven, B. J. & Rogers, P. A. W. Clonality of smooth  
363 muscle and fibroblast cell populations isolated from human and myometrial tissues. *Mol Hum*  
364 *Reprod.* (2014) 20:250-259.doi:10.1093/molehr/gat083  
365 [2] Al-Hendy, A., Myers, E. R. & Stewart, E. Uterine Fibroids: Burden and Unmet Medical Need.  
366 *Semin Reprod Med.* (2017) 35:473-480.doi:10.1055/s-0037-1607264  
367 [3] Stewart, E. A., Laughlin-Tommaso, S. K., Catherino, W. H., Lalitkumar, S., Gupta, D. &

- 368 Vollenhoven, B. Uterine fibroids. *Nat Rev Dis Primers*. (2016) 2:16043.doi:10.1038/nrdp.2016.43
- 369 [4] Ma, L., Xie, S., Zhu, Y. & Cao, L. Research progress of uterine fibroids. *Reproduction and*  
370 *Contraception*. (2007) 27:679-683+687
- 371 [5] Shen, T.-C., Yang, C.-Y., Huang, Y.-J., Lin, C.-L. & Sung, F.-C. Risk of depression in patients with  
372 uterine leiomyoma: A nationwide population-based cohort study. *Journal of Affective Disorders*.  
373 (2017) 213:126-130.doi:10.1016/j.jad.2017.02.020
- 374 [6] Josephine, M., Michael, F., Patricia, T., James, S. & Janeen, D. The economic impact of uterine  
375 fibroids in the United States:a summary of published estimates. *Journal of Women's Health*. (2005)  
376 14:692–703.doi:10.1089/jwh.2005.14.692
- 377 [7] Borahay, M. A., Al-Hendy, A., Kilic, G. S. & Boehning, D. Signaling pathways in leiomyoma:  
378 understanding pathobiology andimplications for therapy. *Molecular Medicine*. (2015)  
379 21:242-256.doi:10.2119/molmed.2014.00053
- 380 [8] Shen, Y., Wu, Y., Lu, Q., Zhang, P. & Ren, M. Transforming growthfactor-b signaling pathway  
381 cross-talking with ERa signaling pathway on regulating the growth of uterine leiomyomaactivated  
382 by phenolic environmental estrogens in vitro. *Tumor Biology*. (2016)  
383 37:455-462.doi:10.1007/s13277-015-3813-4
- 384 [9] Bulun, S. E., Moravek, M. B., Yin, P., Ono, M., 5th, J. S. C., Dyson, M. T., et al. Uterine  
385 leiomyoma stem cells: linking progester-one to growth. *Seminars in Reproductive Medicine* (2015)  
386 33:357-365.doi:10.1055/s-0035-1558451
- 387 [10] Borah, B. J., Laughlin-Tommaso, S. K., Myers, E. R., Yao, X. & Stewart, E. A. Association  
388 between patient characteristics and treatment procedure among patients with uterine leiomyomas.  
389 *Obstetrics & Gynecology*. (2016) 127:67-77.doi:10.1097/AOG.0000000000001160
- 390 [11] Gliklich, R. E., Leavy, M. B. & Velentgas, P. Identification of future research needs in the  
391 comparative management of uter-ine fibroid disease: a report on the priori-ty-setting process,  
392 preliminary data anal-ysis, and research plan. Agency for Healthcare Research and Quality. 2011
- 393 [12] Hanafi, M. Predictors of leiomyoma recurrence after myomectomy. *Obstetrics & Gynecology*.  
394 (2005) 105:877-881.doi:10.1097/01.AOG.0000156298.74317.62
- 395 [13] Merrill, R. M. Hysterectomy surveillance in the United States, 1997 through 2005. *Medical*  
396 *Science Monitor*. (2008) 14:CR24-31
- 397 [14] Zhou, J. & Qu, F. Treating gynaecological disorders with traditional Chinese medicine: a review.  
398 *African journal of traditional, complementary, and alternative medicines : AJTCAM*. (2009)  
399 6:494-517.doi:10.4314/ajtcam.v6i4.57181
- 400 [15] Zhao, H., Li, Y., Xu, Q., Peng, F., Zhao, J., Webb, R. C., et al. Establishment of a rat model for  
401 uterine leiomyomas based on Western and traditional Chinese medicine theories. *Brazilian Journal*  
402 *of Medical and Biological Research*. (2018) 51:e7627.doi:10.1590/1414-431X20187627
- 403 [16] Jiang, P., Wang, X., Dong, C., Bao, Y. & Quan, J. Research on the correlation and progress of  
404 JAK3 in clinical application (review); proceedings of the Chinese Journal of Modern Medicine, F,  
405 2020-09-17 [C].
- 406 [17] Raivola, J., Hammarén, H. M., Virtanen, A. T., Bulleeraz, V., Ward, A. C. & Silvennoinen, O.  
407 Hyperactivation of Oncogenic JAK3 Mutants Depend on ATP Binding to the Pseudokinase  
408 Domain. *Frontiers in Oncology*. (2018) 8:560.doi:10.3389/fonc.2018.00560
- 409 [18] Leonard, W. J. & O'Shea, J. J. Jaks and STATs: biological implications. *Annual Review of*

410 Immunology. (1998) 16:293-322.doi:10.1146/annurev.immunol.16.1.293

411 [19] Ribas, A., Camacho, L. H., Lopez-Berestein, G., Pavlov, D., Bulanagui, C. A., Millham, R., et al.

412 Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T

413 lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. *Journal of Clinical Oncology*.

414 (2005) 23:8968-8977.doi:10.1200/JCO.2005.01.109

415 [20] Malemud, C. J. The role of the JAK/STAT signal pathway in rheumatoid arthritis. *Therapeutic*

416 *Advances in Musculoskeletal Disease*. (2018) 10:117-127.doi:10.1177/1759720X18776224

417 [21] Kortylewski, M., Kujawski, M., Wang, T., Wei, S., Zhang, S., Pilon-Thomas, S., et al. Inhibiting

418 Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immu-nity. *Nature*

419 *Medicine*. (2005) 11:1314-1321.doi:10.1038/nm1325

420 [22] Han, H., Li, D., Qian, R., Xu, X., Huang, Y., Ni, J., et al. To explore the mechanism of Lichong

421 Decoction in inhibiting human uterine fibroid cells from the perspective of whole gene expression

422 profile. *Global Chinese Medicine*. (2015) 8:290-295

423 [23] Xue, C., Xie, J., Zhao, D., Lin, S., Zhou, T., Shi, S., et al. The JAK/STAT3 signallingpathway

424 regulated angiogenesis in an endothelial cell/adi-pose-derived stromal cell co-culture , 3D gel

425 model. *Cell Proliferation*. (2017) 50:e12307.doi:10.1111/cpr.12307

426 [24] Shen, T.-C., Yang, C.-Y., Huang, Y.-J., Lin, C.-L. & Sung, F.-C. Risk of depressionin patients with

427 uterine leiomyoma: A nationwide population-based cohort study. *Journal of Affective Disorders*.

428 (2017) 213:126-130.doi:10.1016/j.jad.2017.02.020

429 [25] Mauskopf, J., Flynn, M., Thieda, P., Spalding, J. & Duchane, J. The economic impact of uterine

430 fibroids in the United States:a summary of published estimates. *Journal of Women's Health*. (2005)

431 14:692-703.doi:10.1089/jwh.2005.14.692

432 [26] Cardozo, E. R., Clark, A. D., Banks, N. K., Henne, M. B., Stegmann, B. J. & Segars, J. H. The

433 estimated annual cost of uterine leiomyomata in the United States. *American Journal of Obstetrics*

434 *and Gynecology*. (2012) 206:211.e211-211.e219.doi:10.1016/j.ajog.2011.12.002

435 [27] Meng, W. & Zhao, W. Study on the effect of the method of replenishing qi and removing stasis on

436 the expression of protein related to proliferation and apoptosis of cultured uterine fibroid cells in

437 vitro. *Chinese Journal of Traditional Chinese Medicine*.

438 (2008).doi:10.13193/j.archtcm.2008.02.15.mengw.038

439 [28] Yao, J. Acupuncture theory of promoting blood circulation and removing stasis and its clinical

440 application. *Zhongguo Zhen Jiu = Chinese acupuncture & moxibustion*. (2015) 35:389-392

441 [29] Wang, Z., Xiao, H., Li, X., Yao, X., Miao, J., Cui, J., et al. Research progress on pharmacological

442 action of taohong siwu decoction. *Modern traditional Chinese medicine*. (2021)

443 41:22-28.doi:10.13424/j.cnki.mtcm.2021.02.005

444 [30] Li, S. Effect of taohong siwu decoction on uterine fibroids and its effect on serum sex hormone

445 levels. *Clinical medicine research and practice*. (2018)

446 3:122-123.doi:10.19347/j.cnki.2096-1413.201812058

447 [31] Kortylewski, M., Kujawski, M., Wang, T., Wei, S., Zhang, S., Pilon-Thomas, S., et al. Inhibiting

448 Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. *Nature*

449 *Medicine*. (2005) 11:1314-1321.doi:10.1038/nm1325

450 [32] Liu, J.-B., Chen, D., Bao, T.-T., Fan, F.-T. & Yu, C. The anticancer effects of atractylenolide III

451 associate with the downregulation of Jak3/Stat3-dependent IDO expression. *Frontiers in*

- 452 Pharmacology. (2020) 10:1505.doi:10.3389/fphar.2019.01505
- 453 [33] Wang, Y., Xu, M. & Xiu, W. Experimental study of tanshinone combined with emodin inhibiting  
454 proliferation and migration of colorectal cancer cells through JAK/STAT3 signaling pathway.  
455 Progress of modern general surgery in China. (2020) 32:679-682+687
- 456 [34] Liu, M. Curcumin mediates JAK/STAT3 signaling pathway to regulate apoptotic migration and  
457 invasion of giant cell tumors of bone. Guangzhou. Southern Medical University (2019).
- 458 [35] Asher, S., Hannah, B.-B., Eyal, M., Neri, L., Y, K. B. & Nathan, R. Inhibition of leiomyoma cell  
459 proliferation in vitro by genistein and the protein tyrosine kinase inhibitor TKS050. Fertility and  
460 Sterility. (2007) 87:127-135.doi:10.1016/j.fertnstert.2006.05.056
- 461 [36] Miguel, F. D., Lee, S. O., Onate, S. A. & Gao, A. C. Stat3 enhances transactivation of steroid  
462 hormone receptors. Nuclear Receptor. (2003) 1:3.doi:10.1186/1478-1336-1-3
- 463 [37] Li, C. Expression of IL-6/STAT3/Cyclin D1 and VEGF signaling pathways in uterine fibroids.  
464 Hefei. Anhui Medical University, (2009).
- 465 [38] Dermani, F. K., Samadi, P., Rahmani, G., Kohlan, A. K. & Najafi, R. PD-1/PD-L1 immune  
466 checkpoint: Potential target for cancer therapy. Journal of Cellular Physiology. (2019)  
467 234:1313-1325.doi:10.1002/jcp.27172
- 468 [39] Fallarino, F. & Grohmann, U. Using an Ancient Tool for Ig-niting and Propagating Immune  
469 Tolerance: IDO as an In-ducer and Amplifier of Regulatory T Cell Functions. Current Medicinal  
470 Chemistry. (2011) 18:2215-2221.doi:10.2174/092986711795656027
- 471 [40] Wing, K., Onishi, Y., Prieto-Martin, P., Yamaguchi, T., Miyara, M., Fehervari, Z., et al. CTLA-4  
472 control over Foxp3+ regulatory T cell function. Science. (2008)  
473 322:271-275.doi:10.1126/science.1160062
- 474 [41] Sho, M., Salama, A. D., Yamada, A., Najafian, N. & Sayegh, M. H. Physiologic regulation of  
475 alloimmune responses in vivo: the role of CTLA4 and TH1/TH2 cytokines. Transplantation  
476 Proceedings. (2001) 33:3826-3828.doi:10.1016/s0041-1345(01)02620-3
- 477 42 Peng, F., Xiong, L. & Peng, C. (-)-Sativan Inhibits Tumor Development and Regulates  
478 miR-200c/PD-L1 in Triple Negative Breast Cancer Cells. Front. Pharmacol. 11, 12,  
479 doi:10.3389/fphar.2020.00251 (2020).
- 480 [43] Peng, F., Tang, H., Du, J., Chen, J. & Peng, C. Isoliquiritigenin Suppresses EMT-Induced  
481 Metastasis in Triple-Negative Breast Cancer through miR-200c/C-JUN/ Formula: see text  
482 -Catenin. The American journal of Chinese medicine 49, 505-523,  
483 doi:10.1142/s0192415x21500233 (2021).
- 484 [44] Peng, F. et al. Isoliquiritigenin Derivative Regulates miR-374a/BAX Axis to Suppress  
485 Triple-Negative Breast Cancer Tumorigenesis and Development. Front. Pharmacol. 11, 11,  
486 doi:10.3389/fphar.2020.00378 (2020).
- 487 [45] Wang, L., Peng, F., Peng, C. & Du, J.-R. Gut Microbiota in Tumor Microenvironment: A Critical  
488 Regulator in Cancer Initiation and Development as Potential Targets for Chinese Medicine. The  
489 American journal of Chinese medicine, 1-18, doi:10.1142/s0192415x21500270 (2021).

490

## 491 **Figure legends**

492 **Figure 1.** Schematic design of the experiment.

493

494 | **Figure 2.** Changes in the size of the uterus. Data are reported as mean ± SD. \* $p < 0.05$ , \*\* $p < 0.01$ ,  
495 | \*\*\* $p < 0.001$  compared with control group; # $p < 0.05$ , ## $p < 0.01$ , ### $p < 0.001$  compared with model  
496 | group (one-way ANOVA and LSD test).

497

498 | **Figure 3.** weight changes of rat. Data are reported as mean ± SD. \* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p <$   
499 |  $0.001$  compared with control group; # $p < 0.05$ , ## $p < 0.01$ , ### $p < 0.001$  compared with model group  
500 | (one-way ANOVA and LSD test).

501

502 | **Figure 4.** Effects of THSW on the Appearance of the Uterus. (A) control group; (B) model group; (C)  
503 | positive group; (D) THSW (18g/ml); (E) THSW (9g/ml); (F) THSW (4.5g/ml).

504

505 | **Figure 5.** Histopathologic examinations of uteruses. (A) control group; (B) model group; (C) positive  
506 | group; (D) THSW (18g/ml); (E) THSW (9g/ml); (F) THSW (4.5g/ml).

507

508 | **Figure 6.** Effect of THSW on activation of JAK3 in uterus. Data are reported as mean ± SD. \* $p < 0.05$ ,  
509 | \*\* $p < 0.01$ , \*\*\* $p < 0.001$  compared with control group; # $p < 0.05$ , ## $p < 0.01$ , ### $p < 0.001$  compared  
510 | with model group (one-way ANOVA and LSD test).

511

512 | **Figure 7.** Effect of THSW on activation of STAT3 in uterus. Data are reported as mean ± SD. \* $p < 0.05$ ,  
513 | \*\* $p < 0.01$ , \*\*\* $p < 0.001$  compared with control group; # $p < 0.05$ , ## $p < 0.01$ , ### $p < 0.001$  compared  
514 | with model group (one-way ANOVA and LSD test).

515

516 | **Figure 8.** Effects of THSW on the expression of INDO and CTLA4 in uterus. (A–C) Representative  
517 | western blotting band of INDO, CTLA4 Data are reported as mean ± SD. \* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p$   
518 |  $< 0.001$  compared with control group; # $p < 0.05$ , ## $p < 0.01$ , ### $p < 0.001$  compared with model group  
519 | (one-way ANOVA and LSD test).

520

# Figures





Figure 1


Schematic design of the experiment






**Figure 2**

Changes in the size of the uterus. Data are reported as mean  $\pm$  SD. \* $P < 0.05$ , \*\* $P < 0.01$ , \*\*\* $P < 0.001$  compared with control group; # $P < 0.05$ , ## $P < 0.01$ , ### $P < 0.001$  compared with model group (one-way ANOVA and LSD test).



**Figure 3**

Weight changes of rats. Data are reported as mean  $\pm$  SD. \* $P < 0.05$ , \*\* $P < 0.01$ , \*\*\* $P < 0.001$  compared with control group; # $P < 0.05$ , ## $P < 0.01$ , ### $P < 0.001$  compared with model group (one-way ANOVA and LSD test)



**Figure 4**

Effects of THSW on the Appearance of the Uterus. (A) control group; (B) model group; (C) positive group; (D) THSW (18g/ml) group; (E) THSW (9g/ml) group; (F) THSW (4.5g/ml)




Figure 5

Histopathologic examinations of uteruses. (A) control group; (B) model group; (C) positive group; (D) THSW (18g/ml) group; (E) THSW (9g/ml) group; (F) THSW (4.5g/ml) group






Figure 6

Effect of THSW on activation of JAK3 in uterus. Data are reported as mean  $\pm$  SD. \*P < 0.05, \*\*P < 0.01, \*\*\*P < 0.001 compared with control group; #P < 0.05, ##P < 0.01, ###P < 0.001 compared with model group (one-way ANOVA and LSD test).



**Figure 7**

Effect of THSW on activation of STAT3 in uterus. Data are reported as mean  $\pm$  SD. \* $P < 0.05$ , \*\* $P < 0.01$ , \*\*\* $P < 0.001$  compared with control group; # $P < 0.05$ , ## $P < 0.01$ , ### $P < 0.001$  compared with model group (one-way ANOVA and LSD test).



**Figure 8**

Effects of THSW on the expression of INDO and CTLA4 in uterus. (A–C) Representative western blotting band of INDO, CTLA4 Data are reported as mean  $\pm$  SD. \* $P < 0.05$ , \*\* $P < 0.01$ , \*\*\* $P < 0.001$  compared with control group; # $P < 0.05$ , ## $P < 0.01$ , ### $P < 0.001$  compared with model group (one-way ANOVA and LSD test).

## Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [SuplenmentaryTable11.docx](#)